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Objectives. We sought to determine whether 6 months of
treatment with the angiotensin-converting enzyme (ACE) inhibi-
tor enalapril can improve conduit artery endothelial function in
young subjects with insulin-dependent diabetes mellitus (IDDM).
Background. Endothelial dysfunction is an early event in
atherogenesis and has been demonstrated in young subjects with
IDDM. ACE inhibitors have been shown to enhance conduit artery
endothelial function in animal experiments and in patients with
established coronary atherosclerosis, although their effect in
IDDM is not known.
Methods. Ninety-one subjects (mean age 30.9 years, range 18 to
44) with stable IDDM but no clinical evidence of vascular disease
were randomized to receive enalapril (20 mg once daily) (46
subjects) or placebo (45 subjects) in a randomized, double-blind,
parallel-group study. Brachial artery flow-mediated dilation
(FMD), an endothelium-dependent stimulus, and response to
glyceryl trinitrate (GTN), which acts directly on vascular smooth
muscle, were assessed noninvasively by means of high resolution
external vascular ultrasound at baseline and after 12 and 24
weeks of treatment.
Results. FMD was inversely correlated with total cholesterol
(r 5 0.22, p 5 0.041) but not with any diabetic variables.
Treatment with enalapril had no significant effect on FMD (p 5
0.67) or response to the endothelial-independent dilator GTN
(p 5 0.45).
Conclusions. These data suggest that impairment of endothelial-
dependent dilation in young subjects with IDDM is not improved
by treatment with the ACE inhibitor enalapril. This lack of
improvement may reflect the complex nature of vascular disease
in IDDM, which can affect both endothelial and smooth muscle
function.
(J Am Coll Cardiol 1998;31:1330–5)
©1998 by the American College of Cardiology
In addition to the clinical consequences of microangiopathy,
subjects with insulin-dependent diabetes mellitus (IDDM)
have increased morbidity and mortality from coronary, cere-
bral and peripheral atherosclerosis (1,2). By the age of 55
years, the cumulative mortality from coronary artery disease
(CAD) can be as high as 30% (1), and furthermore, the
progression of atherosclerosis is greater and the results of
revascularization less effective (3,4). Endothelial dysfunction is
thought to contribute to the pathogenesis of both microangi-
opathy and macrovascular disease in diabetes (5–7) and has
been demonstrated in patients with IDDM from as early as the
second decade of life (8–10). Reduced bioavailability of the
“antiatherogenic” molecule nitric oxide (NO) results in im-
paired endothelium-dependent dilation (11), enhanced plate-
let aggregation, leukocyte/endothelial cell interactions and
smooth muscle cell proliferation and migration (11–15).
The renin–angiotensin system and its inhibition may influ-
ence endothelial function through a number of different path-
ways (16). Angiotensin-II may promote macrophage activation
and smooth muscle cell proliferation, both early events in
atherogenesis (17,18). Free radical generation results in inac-
tivation of NO, enhanced lipid peroxidation and cellular injury
(19,20). Angiotensin-converting enzyme (ACE) inhibitors may
have a beneficial effect on endothelial function by reducing
angiotensin-II levels (16) and also by inhibiting bradykinin
degradation (21). ACE inhibitors have been shown to improve
large-vessel endothelial function in both animal models of
hypercholesterolaemia (22,23) and clinical studies of subjects
with established CAD (24). In IDDM, benefits on the progres-
sion of renal disease have been reported (25,26), but the effects
on large-vessel endothelial function have not been studied. We
therefore investigated the effect of the ACE inhibitor enalapril
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on conduit artery endothelial function in young subjects with
IDDM to determine whether improvements of potential clin-
ical significance could be achieved from an early stage in the
natural history of arterial disease.
Methods
Subjects. Subjects with IDDM .2 years in duration were
selected from a diabetic clinic in London if they fulfilled the
following criteria: 18 to 45 years old, nonsmoker (had not
smoked .2 years, with a total exposure ,1 pack-year), rest
supine blood pressure ,140/90 mmHg, no clinical evidence of
large-vessel atherosclerosis and were taking no vasoactive
medication. One hundred eleven subjects were evaluated with
a detailed clinical history, physical examination and 12-lead
electrocardiogram (ECG). To characterize subjects for the
presence of microvascular disease, two or more timed over-
night urine collections were made to measure urinary albumin
excretion at recruitment and again on completion of the study.
After a 4-week screening phase during which all subjects
received placebo medication, 91 of the 111 subjects with stable
diabetic control (glycosylated hemoglobin [HbA1c] ,14%)
and satisfactory compliance with placebo were entered into the
randomized phase of the study. Reasons for nonrandomization
were high HbA1c in 6 patients, poor cooperation or withdrawal
of consent in 12 and adverse experience in 2.
Study design. The study was designed as a randomized,
double-blind, parallel-group study. During the first 3 weeks,
therapy in each subject was titrated from a starting dose of
5 mg of enalapril or placebo equivalent to a dose of 20 mg or
the maximal dose tolerated. Endothelial function was assessed
noninvasively, at baseline and after 12 and 24 weeks of
treatment by means of high resolution external ultrasound, as
previously described (8,27). Subjects were instructed to con-
tinue their normal diabetic diet and insulin regime for the
duration of the study. No attempt was made to study subjects
under conditions of euglycemia. To do so would have been
logistically difficult and, moreover, would have introduced the
potential confounding influences of a glucose and insulin
infusion on endothelial function. Blood samples were taken at
each visit for full blood count, biochemical analysis and HbA1c
measurement (Rapid EP system, Helena Laboratories). Fast-
ing total cholesterol and plasma triglycerides were measured at
recruitment and on completion of the study by means of the
cholesterol C-system high performance CHOD-PAP and
GPO-PAP high performance enzymatic colorimetric test, re-
spectively (Boehringer-Mannheim GmbH, Diagnostica). High
density lipoprotein (HDL) cholesterol was measured after
precipitation of apoprotein B-containing lipoproteins and low
density lipoprotein (LDL) cholesterol calculated according to
the Friedwald formula (28). The study was approved by the
local research ethics committee, and all subjects gave written
informed consent.
Assessment of endothelial function. Subjects rested supine
for at least 10 min before the first scan and remained supine
throughout the procedure. The right brachial artery was im-
aged in the longitudinal section 2 to 10 cm above the elbow
using a standard 7-MHz linear array transducer supported by a
flexible stereotactic clamp and an Accuson 128XP/10 ultra-
sound system. The center of the artery was identified when the
clearest image of anterior and posterior arterial wall layers was
seen. Depth and gain settings were set to optimize the lumen/
arterial wall interface, and the transmit (focus) zone was set to
the depth of the anterior wall because of the greater difficulty
in evaluating this interface. Machine-operating variables were
not altered for the duration of the study. The image was
magnified using a resolution box function, and rest blood flow
was estimated using pulsed wave Doppler with the cursor set at
70° to the longitudinal axis of the artery and the range gate
(1.5 mm) in the center of the artery. A segment of the artery
was selected for analysis, and 5 s of radiofrequency signal from
this segment was routed to an A-mode tracking device (Inge-
nious Systems, The Netherlands). After careful placement of
volume sample cursors at the vessel wall interfaces, vessel wall
movement was tracked and end-diastolic diameter determined
on a beat by beat basis with a spatial resolution of 50 mm.
Once a stable and clear image was achieved, the transducer
position was fixed, and both the arm and transducer remained
in the same position throughout the study. Hard copy images
of the brachial artery were taken and notes made of the
transducer and arm position, enabling precise reproduction of
conditions and measurement of the same segment of artery at
subsequent visits. Rest brachial artery internal diameter was
measured at end-diastole for consecutive beats over a 5-s
interval, and the mean internal diameter was calculated.
Reactive hyperemia was induced by inflation to 300 mm Hg of
a pneumatic tourniquet placed around the forearm at a site
distal to that being scanned and its rapid release after 4.5 min.
The increase in brachial artery flow over 15 s after cuff release
was determined using pulsed wave Doppler, as described
above. Brachial artery diameter was measured 55 to 65 s after
release of the tourniquet, and flow-mediated dilation (FMD)
was expressed as the percent increase in diameter in response
to reactive hyperemia. After 10 to 15 min rest to allow vessel
recovery, a further rest scan was recorded. Sublingual glyceryl
trinitrate (GTN) (400 mg) was administered, and the response
to this endothelium-independent dilator was assessed after
3 min. Brachial artery flow-mediated dilation (FMD) may be
Abbreviations and Acronyms
ACE 5 angiotensin converting enzyme
CAD 5 coronary artery disease
CI 5 confidence interval
ECG 5 electrocardiogram, electrocardiographic
FMD 5 flow-mediated dilation
GTN 5 glyceryl trinitrate
HbA1c 5 glycosylated hemoglobin
IDDM 5 insulin-dependent diabetes mellitus
LDL 5 low density lipoprotein
NO 5 nitric oxide
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blocked by specific antagonists of NO synthase (29), and
measures of FMD using this technique correlate with invasive
assessments of coronary endothelial function and atheroscle-
rosis (30). Hemodynamic and ECG parameters were moni-
tored throughout the study.
Data analysis. All scans were recorded on super VHS
videotape. Printouts of the A-mode signal and cursor place-
ment were made for each scan. Scans were checked for
technical errors by two independent observers (M.J.M.,
A.E.D.) who had no knowledge of the origin of the scan. Scans
in which the image at subsequent studies was not replicated, a
satisfactory distensibility waveform was not achieved or cursor
placement was incorrect were excluded from the final analysis.
Rest volumetric flow was calculated for each study by multi-
plying the velocity-time integral corrected for angle by the
heart rate and vessel cross-sectional area. This method may
lead to overestimation of blood flow although inaccuracies are
consistent, allowing comparison between visits and between
subjects. Reactive hyperemia was calculated as the ratio of
maximal flow (determined from the pulse wave Doppler signal
and heart rate) during the first 15 s after tourniquet release to
that at baseline and was expressed as the percent increase in flow.
Statistical analysis. Descriptive data are expressed as
mean value 6 SD. Subjects who were withdrawn after random-
ization were included in the analyses up to and including the
time of withdrawal. Changes in the measures of vascular
function were assessed by two-way repeated measure analysis
of variance and adjusted for multiple comparisons using the
Bonferroni test. Simple univariate correlation coefficients were
determined between the measures of baseline endothelial-
dependent and -independent dilation and subject demographic
(age, gender) and diabetic characteristics (duration of diabe-
tes, insulin dose, HbA1c, blood pressure) and lipoprotein
subfractions [triglycerides; total, LDL and HDL cholesterol,
lipoprotein(a)]. These variables were then entered into a
stepwise multiple regression analysis to explore factors that
may determine rest blood flow and vascular responses to
reactive hyperemia and GTN. A similar stepwise multiple
regression model was constructed, with change in FMD over
the duration of the study as the dependent variable and the
addition of treatment group as an independent variable.
Statistical significance was inferred at p , 0.05.
Results
Baseline subject characteristics. Age, levels of lipid sub-
fractions, blood pressure, length of time since diagnosis of
diabetes, total daily insulin dose and HbA1c as a measure of
overall diabetic control were comparable in both groups (Table
1). Only one subject had microalbuminuria (20 to 200 mg/min),
and none had macroproteinuria.
Of the 91 subjects randomized (46 to enalapril, 45 to
placebo), 39 taking enalapril and 43 placebo completed the
study. Five subjects (four with enalapril, one with placebo)
withdrew because of adverse clinical experiences, and four
subjects (three with enalapril, one with placebo) withdrew
because of protocol violations or for administrative reasons.
Forty-three of 46 enalapril and 44 of 45 placebo group patients
achieved titration to the maximal dose (20 mg or placebo
equivalent), although the dose was subsequently reduced in
seven enalapril and six placebo group subjects. The treatments
were well tolerated, and compliance determined by tablet
count was .80% in all but three subjects. Twenty-two enalapril
and 20 placebo group subjects had a clinically adverse event
during the study. Six enalapril and one placebo group subject
complained of cough, and six subjects (4 taking enalapril, 2
placebo) had symptoms of headache or dizziness that were
thought to be related to the study medication. However, no
serious events thought to be related to the study medication
were recorded. Fifteen scans from 12 subjects (9 taking
enalapril, 3 placebo) were withdrawn for technical reasons, as
described above.
There were no significant changes in diabetic control,
insulin requirement or lipid subfractions over the course of the
study (Table 1). Enalapril caused a mean decrease of 3.4 6
10.0 mm Hg of diastolic blood pressure (95% confidence
interval [CI] 26.7 to 20.1), but systolic blood pressure re-
mained unchanged, as did both parameters in the placebo
group.
Vascular function. At baseline, rest vessel size, brachial
artery blood flow, degree of reactive hyperemia, FMD and
dilation in response to GTN were comparable in the enalapril
and placebo groups (Table 1). On univariate analysis, there
was an inverse relation between total cholesterol levels and
FMD (r 5 20.22, p 5 0.041). On stepwise multiple regression
analysis, total cholesterol at baseline, but no other lipoprotein
subfractions or diabetic characteristics, was independently






Age (yr) 29.6 (6.3) 32.1 (6.5)
Duration of IDDM (yr) 12.9 (7.8) 12.5 (8.3)
HbA1c (%) 10.2 (1.6) 10.3 (1.8)
Total daily insulin dose (IU) 57.0 (17.26) 51.6 (20.8)
SBP (mm Hg) 116.9 (10.3) 118.6 (8.7)
DBP (mm Hg) 73.7 (8.8) 74.6 (7.5)
Total cholesterol (mmol/liter) 5.06 (0.89) 5.05 (1.01)
LDL cholesterol (mmol/liter) 3.08 (0.80) 2.95 (0.92)
HDL cholesterol (mmol/liter) 1.53 (0.33) 1.63 (0.38)
Triglycerides (mmol/liter) 0.95 (0.60) 0.95 (0.43)
Lipoprotein(a) (mmol/liter)* 8.65 (0.05–101.80) 8.20 (0.05–103.40)
Vessel diameter (mm) 3.59 (0.57) 3.55 (0.61)
Rest blood flow (ml/min)* 30 (12–119) 24 (8–167)
Reactive hyperemia (%)* 311 (125–653) 354 (125–653)
FMD (%) 1.60 (2.38) 2.31 (2.68)
GTN-mediated dilation (%) 17.47 (8.04) 18.34 (7.56)
*Skewed data expressed as geometric mean (range). Data presented are
mean value (SD), unless otherwise indicated. DBP 5 diastolic blood pressure;
FMD 5 flow-mediated dilation; GTN 5 glyceryl trinitrate; HbA1c 5 glycosylated
hemoglobin; HDL 5 high density lipoprotein; IDDM 5 insulin-dependent
diabetes mellitus; LDL 5 low density lipoprotein; SBP 5 systolic blood pressure.
1332 MULLEN ET AL. JACC Vol. 31, No. 6
ENALAPRIL AND VASCULAR REACTIVITY IN DIABETES May 1998:1330–5
correlated with FMD (beta 20.62, p 5 0.041). Dilation in
response to GTN was independently related to gender (beta
5.24, p 5 0.0026), rest blood flow velocity (beta 266.5, p 5
0.015) and total cholesterol level (beta 22.26, p 5 0.0076). In
a separate stepwise multiple regression analysis, rest blood
flow correlated with vessel diameter (beta 24.3, p , 0.0001)
and inversely with total cholesterol level (beta 28.39, p 5
0.0076) but not with any diabetic variables or blood pressure.
This finding may indicate an abnormality of basal tone in distal
resistance arterioles related to cholesterol levels.
Enalapril had no effect on rest vessel size, brachial artery
blood flow or the degree of reactive hyperemia induced,
suggesting that it did not cause significant vasodilation in this
normotensive cohort. FMD for the whole group at baseline
was 2.17 6 2.69%, considerably reduced compared with that in
nondiabetic subjects of similar age and risk factor profile
previously studied in our laboratory (8) and confirming the
presence of endothelial dysfunction. In subjects treated with
enalapril, mean FMD increased from 1.60 6 2.38% at baseline
to 2.55 6 2.68% and 2.80 6 2.94% at 12 and 24 weeks,
respectively. In the placebo group, FMD also increased from
2.31 6 2.68% to 2.58 6 2.19% and 3.02 6 2.64%, respectively
(Fig. 1). However, the increase in FMD over the duration of
the study did not reach statistical significance (p 5 0.27, 95%
CI 20.19 to 0.67), and there was no significant difference
between responses of the enalapril and placebo groups (p 5
0.671, 95% CI 20.34 to 0.52). Response to the endothelium-
independent dilator GTN did not change significantly in either
group over the duration of the study (p 5 0.25, 95% CI 20.54
to 2.07) or in response to enalapril (p 5 0.44, 95% CI 21.80 to
0.81) (Fig. 2).
Multiple regression analysis was performed to determine
whether any factors in the subjects’ baseline profile or treat-
ment group influenced change in FMD over the study period.
Improvement in FMD was related to baseline FMD, vessel
size, duration of diabetes and systolic blood pressure but not
with dilation in response to GTN, age, HbA1c level, LDL
cholesterol level or treatment group (Table 2).
Discussion
The present study confirmed our previous finding (8) of
marked abnormalities of conduit artery physiology in young,
clinically well subjects with IDDM, despite the absence of
microvascular disease. Vascular dysfunction was related to
total and LDL cholesterol levels but not to measures of recent
metabolic control of diabetes. Despite experimental evidence
of favorable effects of ACE inhibition in early atherosclerosis,
we were unable to demonstrate an improvement in conduit
artery FMD during 6 months of treatment with the ACE
inhibitor enalapril.
ACE inhibitors and vascular function. ACE inhibitors
potentially have a number of beneficial effects on vascular
structure and function, mediated either by the direct inhibition
of the promitogenic and proinflammatory effects of
angiotensin-II, or by enhanced bioavailability of the “anti-
atherogenic” molecule NO (31). Increased NO activity may
result from attenuation of angiotensin-II–mediated production
of superoxide (19,32), which can inactivate NO (20), or
through inhibition of bradykinin degradation, a potent physi-
ologic stimulus for NO release (21,33). Experimental evidence
suggests that ACE inhibition may reduce subendothelial accu-
mulation of macrophages (34,35), inhibit smooth muscle cell
growth and enhance endothelial cell repair factors, which may
be important in the early stages of atherogenesis (17,18,36). In
hypercholesterolemic rabbits, ACE inhibition has been shown
(22,23) to enhance endothelial-dependent dilation and to
reduce the development of atherosclerosis independently of its
blood pressure-lowering effects. In clinical trials, a similar
benefit on coronary endothelial function has been shown (24)
with quinapril in nondiabetic patients with CAD, but no
benefit on atherosclerosis or clinical outcome has been dem-
onstrated.
In the current study, we have investigated a group of young
subjects with IDDM because they are known to be at risk for
developing premature atherosclerosis. We chose subjects with-
out clinical vascular disease or other risk factors for athero-
Figure 1. FMD (mean 6 SEM). There was no significant change in
endothelial-dependent dilation either within or between the treatment
groups (two-way repeated measures analysis of variance adjusted for
multiple comparisons by the Bonferroni test). Solid bars 5 enalapril;
open bars 5 placebo.
Figure 2. GTN-mediated dilation (mean 6 SEM). Enalapril (solid
bars) had no significant effect on endothelial-independent dilation
(two-way repeated measures analysis of variance adjusted for multiple
comparisons by the Bonferroni test). Open bars 5 placebo.





Baseline FMD 20.68 , 0.0001
Vessel diameter 21.54 0.003
Duration of IDDM 20.097 0.004
SBP 20.07 0.029
*Multiple r 5 0.48; F 5 2.42. Abbreviations as in Table 1.
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sclerosis to examine the impact of ACE inhibition on early
abnormalities of endothelial function in IDDM. The majority
of our subjects (90 of 91) did not have microalbuminuria,
which is known to increase the risk of atherosclerosis and to
benefit from ACE inhibitor therapy (1,25,26).
The lack of an improvement after enalapril treatment
compared with placebo may have a number of explanations.
There was a trend toward an increase in FMD in both the
enalapril and placebo groups. The reason for the placebo
group improvement may reflect subtle changes in subject
behavior during the study that we were unable to detect or
control, and it remains possible that a significant result would
have been achieved with a greater number of subjects or a
longer study period. We chose to study subjects over 6 months
because this period has been shown (24) to result in significant
improvement in coronary endothelial function in patients with
CAD treated with quinapril when, intuitively, disease is likely
to be more advanced and resistant to therapy.
A second factor may be the greater importance of the
renin–angiotensin system in established atherosclerosis. Re-
cent evidence (37) suggests that expression of ACE inhibitors
in conduit artery endothelium may be low in the absence of
atherosclerotic plaque, and the beneficial effects of ACE
inhibition seen in animal and human studies may therefore
reflect a greater impact on more advanced atherosclerotic
disease. Furthermore, the vasoprotective effects of ACE inhib-
itors may depend on their ability to inhibit tissue-bound as
opposed to circulating ACE (38). The potency of individual
ACE inhibitors may be influenced by their pharmacologic
properties, such as lipid solubility, affinity for ACE in vascular
tissues and their clearance (39). Our findings with enalapril
cannot therefore be extrapolated to other ACE inhibitors.
Endothelial function in IDDM. The complex nature of
vascular injury in IDDM, which affects both endothelial and
smooth muscle cell function, may be less responsive to inter-
vention than that seen in young subjects with early risk factors,
such as hypercholesterolemia (40). This may influence the
ability to detect changes in endothelial function using this
noninvasive technique. Endothelial dysfunction in IDDM may
result from enhanced effects of general cardiovascular risk
factors, including hypertension and a shift to an atherogenic
lipoprotein profile (41), as well as factors specific to IDDM
affecting both NO production and breakdown. Oxidative stress
is increased, and levels of the antioxidant vitamins E and C,
catalase and superoxide dismutase may all be reduced in
diabetic tissues (42). Nonenzymatic glycosylation of proteins
may lead to the formation of advanced glycosylation end
products that may also inactivate NO, initiate lipid peroxida-
tion and cause endothelial damage after uptake by specific
cellular receptors (43–45). NO production may also be de-
creased as a result of defects of NO synthase or decreased
availability of L-arginine, the substrate for NO synthesis
(46,47). Noninvasive assessment of endothelial function relies
on the contrast between endothelial-dependent and
-independent vasodilation, so that endothelial-derived NO
activity (29) can be determined. In addition to abnormalities of
FMD, impaired response to the smooth muscle dilator GTN
has been demonstrated in diabetic patients (8) and may limit
the sensitivity of our methodology to detect subtle improve-
ments in endothelial function in response to intervention.
Our previous work (8) has indicated that the abnormalities
of conduit vascular function in IDDM were related to duration
rather than control of diabetes. The present study extends
these findings by demonstrating that for the whole cohort,
duration of diabetes was also related to improvement in FMD
over 6 months, although we cannot ascribe this result to a
treatment effect of enalapril. This finding is in accord with
clinical studies in which tight metabolic control has had
disappointing results on the progression of large-vessel athero-
sclerosis in IDDM (48). Despite our inclusion of a relatively
young cohort of subjects with IDDM, earlier intervention may
be required to achieve greatest benefit.
Although the renin–angiotensin system may have a role in
the pathogenesis of vascular disease, the complex nature of this
process in IDDM may be resistant to individual strategies
aimed at restoring vascular function. Thus, in addition to
specific therapies, including ACE inhibition, an approach that
targets reduction of modifiable risk factors, such as hypercho-
lesterolemia, known to be associated with early endothelial
damage, or aimed at enhancing endothelial production of NO
may be required to limit the clinical impact of large-vessel
atherosclerosis in IDDM.
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